Press Release Details

View all news

Quest Diagnostics to Speak at The Thomas Weisel Partners Tailwinds 2004 Conference


TETERBORO, N.J., Sept. 7 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that Robert A. Hagemann, Senior Vice President and Chief Financial Officer, is scheduled to speak at the Thomas Weisel Partners Tailwinds Conference on Wednesday, September 8, 2004, at The Four Seasons Hotel in Boston, Massachusetts. The Quest Diagnostics presentation is scheduled to begin at 8:00 a.m. Eastern Time.

During the conference the company will reiterate its third quarter 2004 guidance of approximately 6% revenue growth, operating income to exceed 18% of revenues, and earnings per diluted share between $1.25 and $1.30. This guidance does not include the impact from the recent hurricanes in Florida, which will take some time for the company to fully assess.

The presentation will be webcast live during the conference and will be available to registered investors on the following site: and to the public on In addition, the archived webcast will be available starting two hours after the presentation.

Quest Diagnostics Incorporated is the nation's leading provider of diagnostic testing, information and services, providing insights that enable healthcare professionals to make decisions that improve health. The company offers the broadest access to diagnostic testing services through its national network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is the leading provider of esoteric testing, including gene-based medical testing, and provides advanced information technology solutions to improve patient care. Additional company information is available at:

The statements in this press release which are not historical facts or information may be forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results and outcomes to be materially different. Certain of these risks and uncertainties may include, but are not limited to, competitive environment, changes in government regulations, changing relationships with customers, payers, suppliers and strategic partners and other factors described in the Quest Diagnostics Incorporated 2003 Form 10-K and subsequent filings.

SOURCE Quest Diagnostics Incorporated
-0- 09/07/2004
/CONTACT: Investors, Laure Park, +1-201-393-5030, or Media, Jennifer
Somers, +1-201-393-5700, both of Quest Diagnostics/
/Web site: /

Categories: Press Releases
View all news